Back to Journals » Drug Design, Development and Therapy » Volume 13

Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia

Authors Niu B, Zhang H, Li C, Yan F, Song Y, Hai G, Jiao Y, Feng Y

Received 7 March 2019

Accepted for publication 18 June 2019

Published 5 September 2019 Volume 2019:13 Pages 3009—3019

DOI https://doi.org/10.2147/DDDT.S207955

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sukesh Voruganti


Bingxuan Niu,1 Hui Zhang,1 Chunyan Li,2 Fulin Yan,1,2 Yu Song,1 Guangfan Hai,1 Yunjuan Jiao,3 Yansheng Feng3

1College of Pharmacy, Xinxiang Medical University, Xingxiang, Henan Province 453003, People’s Republic of China; 2Sanquan College of Xinxiang Medical University, Xinxiang, Henan Province 453002, People’s Republic of China; 3Basic Medical College, Xinxiang Medical University, Xinxiang, Henan Province 453003, People’s Republic of China

Correspondence: Fulin Yan
College of Pharmacy, Xinxiang Medical University, 601 Jinsui Avenue, Hongqi District, Xingxiang, Henan Province 453003, People’s Republic of China
Tel +1 378 251 3326
Email yannz2009@163.com

Objective: The aim of this study was to identify the active anti-ischemic components of Pterocypsela elata (P. elata) using a network pharmacology approach to construct an effective component anti-cerebral ischemic target network and systematically analyze this medicinal material.
Methods: Pharmacological studies have shown that P. elata has an obvious effect against cerebral ischemia. To identify the potential targets, 14 components of P. elata were docked to each structural element of the targets in the DRAR-CPI database by reverse docking technology. We then compared the identified potential targets with FDA-approved targets for stroke/cerebral infarction treatment in the DrugBank database and identified the active components of P. elata and their potential targets for stroke/cerebral infarction treatment. The active component-target networks were constructed using Cytoscape 3.5.1 software. The target protein-protein interactions were analyzed using the STRING database. KEGG pathway analysis and gene ontology (GO) enrichment analysis were performed through the Database for Annotation, Visualization and Integrated Discovery (DAVID).
Results: There were 14 active components identified from P. elata and 21 potential targets identified for cerebral ischemia treatment, including carbonic anhydrase 2, ribosyldihydronicotinamide dehydrogenase, cholinesterase, and glutathione S-transferase P. The main involved pathways include metabolic pathways, complement and coagulation cascades and steroid hormone biosynthesis.
Conclusion: Through a network pharmacology approach, we predicted the active components of P. elata and their potential targets for cerebral ischemia treatment. Our results provide new perspectives and clues for further studies on the anti-cerebral ischemia mechanism of P. elata.

Keywords: network pharmacology, Pterocypsela elata, cerebral ischemia, molecular docking

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]